Creative Medical Technology (OTCMKTS:CELZ) Versus Genocea Biosciences (NASDAQ:GNCA) Head-To-Head Comparison
Creative Medical Technology (OTCMKTS:CELZ) Versus Genocea Biosciences (NASDAQ:GNCA) Head-To-Head Comparison
Genocea Biosciences (NASDAQ:GNCA – Get Rating) and Creative Medical Technology (OTCMKTS:CELZ – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.
基因生物科技(納斯達克：GNCA-GET評級)和創新醫療科技(OTCMKTS：CELZ-GET評級)都是小盤醫療公司，但哪隻股票更好？我們將根據分析師的建議、估值、機構所有權、股息、收益、盈利能力和風險對這兩家公司進行對比。
Profitability
盈利能力
This table compares Genocea Biosciences and Creative Medical Technology's net margins, return on equity and return on assets.
此表比較了Genocea Biosciences和Creative Medical Technology的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Genocea Biosciences | N/A | -182.88% | -62.76% |
| Creative Medical Technology | -9,516.90% | -48.25% | -46.65% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| Genocea生物科學 | 不適用 | -182.88% | -62.76% |
| 創新醫療技術 | -9,516.90% | -48.25% | -46.65% |
Valuation and Earnings
估值和收益
This table compares Genocea Biosciences and Creative Medical Technology's revenue, earnings per share (EPS) and valuation.
此表比較了Genocea Biosciences和Creative Medical Technology的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genocea Biosciences | $1.64 million | 0.28 | -$33.20 million | ($0.61) | -0.01 |
| Creative Medical Technology | $90,000.00 | 61.25 | $19.21 million | N/A | N/A |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| Genocea生物科學 | 164萬美元 | 0.28 | -3320萬美元 | ($0.61) | -0.01 |
| 創新醫療技術 | $90,000.00 | 61.25 | 1,921萬美元 | 不適用 | 不適用 |
Institutional & Insider Ownership
機構與內部人持股
9.3% of Genocea Biosciences shares are held by institutional investors. Comparatively, 10.7% of Creative Medical Technology shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 2.8% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Genocea Biosciences 9.3%的股份由機構投資者持有。相比之下，創新醫療科技10.7%的股份由機構投資者持有。Genocea Biosciences 1.6%的股份由公司內部人士持有。相比之下，創新醫療技術公司2.8%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、對衝基金和大型基金管理公司相信，一家公司有望實現長期增長。
Analyst Ratings
分析師評級
This is a breakdown of recent recommendations for Genocea Biosciences and Creative Medical Technology, as provided by MarketBeat.com.
這是由MarketBeat.com提供的關於基因生物科學和創新醫療技術的最新建議的細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genocea Biosciences | 0 | 2 | 0 | 0 | 2.00 |
| Creative Medical Technology | 0 | 0 | 1 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| Genocea生物科學 | 0 | 2 | 0 | 0 | 2.00 |
| 創新醫療技術 | 0 | 0 | 1 | 0 | 3.00 |
Genocea Biosciences presently has a consensus price target of $3.00, suggesting a potential upside of 37,874.68%. Creative Medical Technology has a consensus price target of $10.00, suggesting a potential upside of 2,453.63%. Given Genocea Biosciences' higher probable upside, equities research analysts clearly believe Genocea Biosciences is more favorable than Creative Medical Technology.
Genocea Biosciences目前的共識目標價為3.00美元，這意味着潛在的上漲幅度為37,874.68%。創新醫療技術公司的一致目標價為10.00美元，這意味着潛在的上漲幅度為2,453.63%。鑑於Genocea Biosciences更有可能上行，股票研究分析師顯然認為Genocea Biosciences比Creative Medical Technology更有利。
Summary
摘要
Creative Medical Technology beats Genocea Biosciences on 8 of the 11 factors compared between the two stocks.
在兩隻股票的11個指標中，創新醫療技術公司有8個指標超過了Genocea Bioscions。
About Genocea Biosciences
關於Genocea生物科學
(Get Rating)
(獲取評級)
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
生物製藥公司Genocea Biosciences，Inc.發現和開發新的癌症免疫療法。該公司使用其專有的發現平臺ATLAS，該平臺描述了每個患者對下一代腫瘤測序確定的每個目標或抗原的CD4+和CD8+T細胞免疫反應。它的產品包括Gen-011，這是一種過繼的T細胞療法，正處於治療實體腫瘤的1/2a階段臨牀試驗；以及Gen-009，它是一種新抗原候選疫苗，正處於1/2a階段的臨牀試驗，提供跨越ATLAS識別的抗腫瘤新抗原的輔助性合成長肽。該公司成立於2006年，總部設在馬薩諸塞州劍橋市。2022年7月5日，Genocea Biosciences，Inc.根據破產法第11章向美國馬薩諸塞州地區破產法院提交了自願重組請願書。
About Creative Medical Technology
關於創新醫療技術
(Get Rating)
(獲取評級)
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Creative Medical Technology Holdings，Inc.是一家生物技術公司，專注於免疫學、泌尿學、整形外科和使用成人幹細胞治療的神經學。該公司提供CiverStem用於治療勃起功能障礙；FemCelz用於治療生殖器敏感性喪失和乾燥；StemSpine用於治療慢性下腰痛；ImmCelz用於治療中風患者；以及OvaStem用於治療女性不孕症。創新醫療技術控股公司總部設在亞利桑那州鳳凰城。
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Genocea Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。